Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Though great progress has been made in the treatment of SCLC in recent years, only two PD-L1
therapies are currently approved, treatment options are limited, and patient survival remains
to be further improved. The current study aims to investigate the efficacy and safety of
surufatinib combined with durvalumab combined with EP/EC regimen in first-line treatment of
patients with extensive-stage SCLC, and to further explore the predictive biomarkers of this
treatment combination.